Agent tag sponsored by:
Agent
-
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting :: Actinium Phar
ir.actiniumpharma.com | | Article Details | Related Articles